UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2015.
Commission File Number: 000-53805
Intellipharmaceutics International Inc.
(Translation of registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F. Form 20-F [ x ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1):
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form
6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public
under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home
country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the
report or other document is not a press release, is not required to be and has not been distributed to the registrant's security
holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing
on EDGAR.
On October 9, 2015, the Registrant issued a news release, a copy of which is attached hereto
as Exhibit 99.1 and incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Intellipharmaceutics International Inc.
(Registrant)
|
Date: October 9, 2015 |
|
/s/ Domenic Della Penna
Domenic Della Penna
Chief Financial Officer |
EXHIBIT LIST
Exhibit |
Description |
99.1 |
News Release dated October 9, 2015 - Intellipharmaceutics to Present at Dawson James Securities Growth Stock Conference |
|
|
2
Exhibit 99.1
Intellipharmaceutics to Present at Dawson James Securities
Growth Stock Conference
TORONTO, October 9, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International
Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing
in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs,
today announced that the Company is scheduled to present at the Dawson James Securities Growth Stock Conference on October 15,
2015. The presentation will take place at 11:45 A.M. (EDT) in the Wyndham Grand Hotel in Jupiter, Florida.
The presentation may be accessed through the Investor Relations’ Events and
Presentations section on Intellipharmaceutics’ website at www.intellipharmaceutics.com.
About Intellipharmaceutics
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in
the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.
The Company's patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be
applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, Intellipharmaceutics
has developed several drug delivery systems and a pipeline of products (our dexmethylphenidate hydrochloride extended-release capsules
for the 15 and 30 mg strengths which received final United States Food and Drug Administration (“FDA”) approval) and
product candidates in various stages of development, including Abbreviated New Drug Applications (“ANDAs ”) filed with
the FDA (and one Abbreviated New Drug Submissions (“ANDSs”) filed with Health Canada) in therapeutic areas that include
neurology, cardiovascular, gastrointestinal tract, diabetes and pain.
Intellipharmaceutics also has New Drug Application (“NDA”) 505(b)(2) specialty
drug product candidates in its development pipeline. These include Rexista™ Oxycodone XR, an abuse deterrent oxycodone based
on its proprietary nPODDDS™ novel Point Of Divergence Drug Delivery System and PODRAS™ Paradoxical OverDose Resistance
Activating System, and Regabatin™ XR pregabalin extended-release capsules. Our current development effort is increasingly
directed towards improved difficult-to-develop controlled-release drugs which follow an NDA 505(b)(2) regulatory pathway. The Company
has increased its research and development emphasis towards new product development, facilitated by the 505(b)(2) regulatory pathway,
by advancing the product development program for both Rexista™ and Regabatin™. The 505(b)(2) pathway (which relies
in part upon the approving agency’s findings for a previously approved drug) both accelerates development timelines and reduces
costs in comparison to NDAs for new chemical entities. An advantage of our strategy for development of NDA 505(b)(2) drugs is that
our product candidates can, if approved for sale by the FDA, potentially enjoy an exclusivity period which may provide for greater
commercial opportunity relative to the generic ANDA route.
Certain statements in this document and the upcoming
presentation constitute "forward-looking statements" within the meaning of the United States Private Securities
Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These
statements include, without limitation, statements expressed or implied regarding our plans, goals and milestones, status of
developments or expenditures relating to our business, plans to fund our current activities, statements concerning our
partnering activities, health regulatory submissions, strategy, future operations, future financial position, future sales,
revenues and profitability, projected costs, and market penetration. In some cases, you can identify forward-looking
statements by terminology such as "may," "will," "should," "expects,"
"plans," “plans to,” "anticipates," "believes," "estimates,"
"predicts," "potential," "continue," "intends," "could," or the negative of
such terms or other comparable terminology. We made a number of assumptions in the preparation of our
forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a
multitude of known and unknown risks and uncertainties that could cause actual results, future circumstances or events to
differ materially from those stated in or implied by the forward-looking statements. Risks, uncertainties and other factors
that could affect our actual results include, but are not limited to, the effects of general economic conditions, securing
and maintaining corporate alliances, our estimates regarding our capital requirements, and the effect of capital market
conditions and other factors, including the current status of our product development programs, on capital availability, the
potential dilutive effects of any future financing and the expected use of any proceeds from any offering of our securities,
our ability to maintain compliance with the continued listing requirements of the principal markets on which our securities
are traded, our programs regarding research, development and commercialization of our product candidates, the timing of such
programs, the timing, costs and uncertainties regarding obtaining regulatory approvals to market our product candidates and
the difficulty of predicting the timing and results of any product launches, and the timing and amount of any available
investment tax credits, the actual or perceived benefits to users of our drug delivery technologies, products and product
candidates as compared to others, our ability to establish and maintain valid and enforceable intellectual property rights in
our drug delivery technologies, products and product candidates, the scope of protection provided by intellectual property
for our drug delivery technologies, products and product candidates, the actual size of the potential markets for any of our
products and product candidates compared to our market estimates, our selection and licensing of products and product
candidates, our ability to attract distributors and collaborators with the ability to fund patent litigation and with
acceptable development, regulatory and commercialization expertise and the benefits to be derived from such collaborative
efforts, sources of revenues and anticipated revenues, including contributions from distributors and collaborators, product
sales, license agreements and other collaborative efforts for the development and commercialization of product candidates,
our ability to create an effective direct sales and marketing infrastructure for products we elect to market and sell
directly, the rate and degree of market acceptance of our products, delays that may be caused by changing regulatory
requirements, the difficulty in predicting the timing of regulatory approval and the timing of launch of competitive
products, the difficulty of predicting the impact of competitive products on volume and pricing, the inability to forecast
wholesaler demand and/or wholesaler buying patterns, the seasonal fluctuation in the numbers of prescriptions written for our
dexmethylphenidate hydrochloride extended-release capsules which may produce substantial fluctuations in revenues, the timing
and amount of insurance reimbursement for our products, changes in the laws and regulations, including Medicare and Medicaid,
affecting among other things, pricing and reimbursement of pharmaceutical products, the success and pricing of other
competing therapies that may become available, our ability to retain and hire qualified employees, the availability and
pricing of third party sourced products and materials, difficulties or delays in manufacturing, the manufacturing capacity of
third-party manufacturers that we may use for our products, the successful compliance with FDA, Health Canada and other
governmental regulations applicable to the Company and its third party manufacturers' facilities, products and/or businesses,
difficulties, delays or changes in the FDA approval process or test criteria for ANDAs and NDAs and risks associated with
cyber-security and vulnerability of the Company’s digital information and the digital information of the
Company’s commercialization partner(s). Additional risks and uncertainties relating to the Company and our business can
be found in the "Risk Factors" section of our latest annual information form, our latest Form 20-F, and our latest
Form F-3 (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports,
public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada and the
U.S., which are available on www.sedar.com and www.sec.gov. The forward-looking statements reflect our current views with
respect to future events and are based on what we believe are reasonable assumptions as of the date of this document, and we
disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Company Contact:
Intellipharmaceutics International Inc.
Domenic Della Penna
Chief Financial Officer
416-798-3001 ext 106
investors@intellipharmaceutics.com
Investor Contact:
ProActive Capital
Kirin Smith
646-863-6519
ksmith@proactivecapital.com
IntelliPharmaCeutics (QB) (USOTC:IPCIF)
Historical Stock Chart
From Apr 2024 to May 2024
IntelliPharmaCeutics (QB) (USOTC:IPCIF)
Historical Stock Chart
From May 2023 to May 2024